Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
- Status
- UNKNOWN
- Phase
- PHASE2
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
MUK Nine b: OPTIMUM Treatment Protocol
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
- Status
- TERMINATED
- Phase
- PHASE4
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- Status
- RECRUITING
- Phase
- PHASE1
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
- Status
- TERMINATED
- Phase
- PHASE1
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2